ResearcherUniversity of California, IrvineActive in the last 2 years
Alica K. Michels
Matched on ORCID iD 0009-0005-9573-0333; OpenAlex author ID A5140849887. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 39
2025: 1 paper · 2026: 3 papers
Papers 4
- Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.jcmgh.2026.101872↗
- Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
- ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
- Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer Co-author DOI 10.1101/2025.09.04.673818↗
Closest collaborators
The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher J. Halbrook · 4 shared papers, 2025–2026 · strength 0.79
- Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer DOI 10.1101/2025.09.04.673818↗
- Austin D. Silva · 3 shared papers, 2026 · strength 0.61
- Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Rima Singh · 3 shared papers, 2026 · strength 0.61
- Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Alexander Muir · 2 shared papers, 2025–2026 · strength 0.39
- Alexander Kleger · 2 shared papers, 2026 · strength 0.38
- Thomas Theodor Werner Seufferlein · 2 shared papers, 2026 · strength 0.38
- Oliver Gene McDonald · 1 shared paper, 2026 · strength 0.23
- Nikki K. Lytle · 1 shared paper, 2026 · strength 0.23
- Nina G. Steele · 1 shared paper, 2026 · strength 0.23
- David K. Imagawa · 1 shared paper, 2026 · strength 0.23
- Ian M. Loveless · 1 shared paper, 2026 · strength 0.23
- Zeljka Jutric · 1 shared paper, 2026 · strength 0.23
- Mohammed Aldakkak · 1 shared paper, 2026 · strength 0.23
- Jennifer P. Morton · 1 shared paper, 2026 · strength 0.23
- Jennifer Brooke Valerin · 1 shared paper, 2026 · strength 0.20
- Chantal Allgöwer · 1 shared paper, 2026 · strength 0.20
- Tim Eiseler · 1 shared paper, 2026 · strength 0.20
- Kevin Christian Montecillo Gulay · 1 shared paper, 2026 · strength 0.20
- Aimee L Edinger · 1 shared paper, 2026 · strength 0.20
- David Kuang-Fu Chang · 1 shared paper, 2026 · strength 0.20
- Hervé Tiriac · 1 shared paper, 2026 · strength 0.20
- Colin S. Sheehan · 1 shared paper, 2025 · strength 0.19
- Kay F. Macleod · 1 shared paper, 2025 · strength 0.19
- Leah Marie Ziolkowski · 1 shared paper, 2025 · strength 0.19
- Guillaume Cognet · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.